# Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

> **NCT00615589** · PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- Multiple Myeloma
- Plasma Cell Leukemia

## Interventions

- **DRUG:** Fludarabine/Busulfan x 4 days
- **PROCEDURE:** stem cell transplant

## Key facts

- **NCT ID:** NCT00615589
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2012-12
- **Final completion:** 2013-01
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2016-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00615589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00615589, "Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00615589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*